Supplemental Materials, Supplementary Tables 1-3 from A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Year: 2023
Type: supplementary-materials
Abstract: Table S1:Summary of baseline pathological diagnosis; Table S2:Noncompartmental Pharmacokinetic Summary Following Oral Administration of ralimetinib on Day 1 and on Day 14 (Cycle 1) - Capsule Formulation; Table S3: Noncompartmental Pharmacokinetic Summary Following Oral Administration of ralimetinib on Day 1 and on Day 14 (Cycle 1) - Tablet Formulation
Authors: Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R. Molina, Drew W. Rasco, Rebecca R. Arcos, Claudia S. Kelly, Sameera R. Wijayawardana, Xuekui Zhang, Louis F. Stancato, Robert Bell, Peipei Shi, Palaniappan Kulanthaivel, Celine Pitou, Lynette B. Mulle, Daphne L. Farrington, Edward M. Chan, Matthew P. Goetz
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361915920